Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation
Yue Zhou(Shanghai Medical College of Fudan University), Tingbo Liang(Zhejiang University)
Cited by 95
Related Papers
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
|Signal Transduction and Targeted Therapy|2021|594
Oncolytic virotherapy: basic principles, recent advances and future directions
|Signal Transduction and Targeted Therapy|2023|386
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243
mRNA vaccines in disease prevention and treatment
|Signal Transduction and Targeted Therapy|2023|217